0.9708
price down icon3.88%   -0.0392
after-market After Hours: 1.01 0.0392 +4.04%
loading
Fate Therapeutics Inc stock is traded at $0.9708, with a volume of 1.28M. It is down -3.88% in the last 24 hours and down -10.94% over the past month. Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
See More
Previous Close:
$1.01
Open:
$1
24h Volume:
1.28M
Relative Volume:
0.88
Market Cap:
$111.96M
Revenue:
$13.45M
Net Income/Loss:
$-178.23M
P/E Ratio:
-0.5884
EPS:
-1.65
Net Cash Flow:
$-132.53M
1W Performance:
-2.92%
1M Performance:
-10.94%
6M Performance:
+7.54%
1Y Performance:
-71.86%
1-Day Range:
Value
$0.961
$1.00
1-Week Range:
Value
$0.9403
$1.03
52-Week Range:
Value
$0.6611
$3.795

Fate Therapeutics Inc Stock (FATE) Company Profile

Name
Name
Fate Therapeutics Inc
Name
Phone
858.875.1803
Name
Address
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Name
Employee
181
Name
Twitter
@fatethx
Name
Next Earnings Date
2025-08-08
Name
Latest SEC Filings
Name
FATE's Discussions on Twitter

Compare FATE with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
FATE
Fate Therapeutics Inc
0.9708 116.48M 13.45M -178.23M -132.53M -1.65
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
381.87 96.56B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
449.58 60.08B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
555.51 61.15B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ARGX
Argen X Se Adr
711.09 44.66B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
328.71 36.23B 3.81B -644.79M -669.77M -6.24

Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-18-24 Upgrade BofA Securities Underperform → Neutral
Jun-17-24 Upgrade Piper Sandler Neutral → Overweight
Mar-27-23 Resumed Wells Fargo Equal Weight
Jan-24-23 Downgrade H.C. Wainwright Buy → Neutral
Jan-06-23 Downgrade BMO Capital Markets Outperform → Market Perform
Jan-06-23 Downgrade BofA Securities Buy → Underperform
Jan-06-23 Downgrade Cowen Outperform → Market Perform
Jan-06-23 Downgrade Piper Sandler Overweight → Neutral
Jan-06-23 Downgrade Stifel Buy → Hold
Jan-06-23 Downgrade Truist Buy → Hold
Jan-06-23 Downgrade Wedbush Outperform → Neutral
Jan-03-23 Downgrade Guggenheim Buy → Neutral
Dec-22-22 Downgrade Oppenheimer Outperform → Perform
Dec-15-22 Initiated Goldman Sell
Nov-04-22 Resumed Cantor Fitzgerald Overweight
Oct-10-22 Initiated Canaccord Genuity Buy
Aug-18-22 Resumed Wells Fargo Overweight
Jul-28-22 Initiated Needham Hold
Jul-11-22 Upgrade BMO Capital Markets Market Perform → Outperform
Jun-03-22 Initiated Robert W. Baird Neutral
Feb-11-22 Resumed BMO Capital Markets Market Perform
Dec-15-21 Upgrade Wedbush Neutral → Outperform
Dec-07-21 Initiated Cowen Outperform
Nov-09-21 Upgrade Citigroup Neutral → Buy
Aug-26-21 Initiated Morgan Stanley Equal-Weight
Jun-07-21 Upgrade H.C. Wainwright Neutral → Buy
May-07-21 Upgrade Wedbush Neutral → Outperform
Apr-26-21 Resumed Jefferies Buy
Feb-26-21 Initiated BofA Securities Buy
Feb-26-21 Downgrade Wedbush Outperform → Neutral
Feb-11-21 Downgrade Citigroup Buy → Neutral
Jan-27-21 Resumed H.C. Wainwright Neutral
May-13-20 Initiated H.C. Wainwright Buy
Mar-04-20 Initiated Barclays Overweight
Jan-09-20 Downgrade BMO Capital Markets Outperform → Market Perform
Dec-30-19 Reiterated Mizuho Buy
Dec-09-19 Upgrade Wells Fargo Market Perform → Outperform
Nov-12-19 Initiated SunTrust Buy
Nov-06-19 Downgrade Wells Fargo Outperform → Market Perform
Oct-01-19 Initiated Stifel Buy
Aug-09-19 Initiated BTIG Research Buy
Jul-22-19 Initiated Cantor Fitzgerald Overweight
Jul-12-19 Initiated Oppenheimer Outperform
Jun-13-19 Initiated Mizuho Buy
Jun-07-19 Initiated ROTH Capital Neutral
May-31-19 Initiated Guggenheim Buy
May-24-19 Resumed Citigroup Buy
Mar-28-19 Initiated SVB Leerink Outperform
Jan-03-19 Downgrade Stephens Overweight → Equal-Weight
Nov-05-18 Initiated Jefferies Buy
Aug-01-18 Initiated Citigroup Buy
Mar-06-18 Downgrade H.C. Wainwright Buy → Neutral
View All

Fate Therapeutics Inc Stock (FATE) Latest News

pulisher
Sep 25, 2025

Fate Therapeutics (NASDAQ:FATE) Stock Crosses Below 200-Day Moving AverageHere's What Happened - MarketBeat

Sep 25, 2025
pulisher
Sep 24, 2025

Fate Therapeutics Inc. stock daily chart insightsJuly 2025 Selloffs & Weekly Watchlist for Consistent Profits - newser.com

Sep 24, 2025
pulisher
Sep 23, 2025

Stem Cell Co. Beats Investor Suit Over Failed Janssen Collab - Law360

Sep 23, 2025
pulisher
Sep 23, 2025

Fate Therapeutics Gets J&J Partnership Class Action Tossed Again - Bloomberg Law News

Sep 23, 2025
pulisher
Sep 22, 2025

Top chart patterns to watch in Fate Therapeutics Inc.Insider Buying & AI Enhanced Trade Execution Alerts - newser.com

Sep 22, 2025
pulisher
Sep 22, 2025

Evaluating Fate Therapeutics Inc. with trendline analysisWeekly Trend Summary & AI Driven Price Predictions - newser.com

Sep 22, 2025
pulisher
Sep 20, 2025

Fate Therapeutics, Inc. $FATE Shares Bought by Acadian Asset Management LLC - MarketBeat

Sep 20, 2025
pulisher
Sep 20, 2025

Applying big data sentiment scoring on Fate Therapeutics Inc.2025 EndofYear Setup & Growth Focused Stock Pick Reports - newser.com

Sep 20, 2025
pulisher
Sep 20, 2025

Options Flow: Can Fate Therapeutics Inc ride the EV waveIndex Update & Weekly Setup with ROI Potential - خودرو بانک

Sep 20, 2025
pulisher
Sep 20, 2025

Aug PreEarnings: Is Fate Therapeutics Inc. subject to activist investor interestTrend Reversal & Fast Entry High Yield Stock Tips - خودرو بانک

Sep 20, 2025
pulisher
Sep 19, 2025

Will Fate Therapeutics Inc. rebound enough to break even2025 Technical Overview & Daily Stock Trend Watchlist - newser.com

Sep 19, 2025
pulisher
Sep 19, 2025

Aug PostEarnings: Is Fate Therapeutics Inc in a bullish channel2025 Retail Activity & Consistent Growth Equity Picks - خودرو بانک

Sep 19, 2025
pulisher
Sep 19, 2025

Using Ichimoku Cloud for Fate Therapeutics Inc. technicalsEarnings Beat & Technical Entry and Exit Alerts - newser.com

Sep 19, 2025
pulisher
Sep 19, 2025

Insider Buy: What is the dividend yield of Fate Therapeutics IncQuarterly Portfolio Review & AI Driven Stock Price Forecasts - khodrobank.com

Sep 19, 2025
pulisher
Sep 19, 2025

MACD Signal: Is Fate Therapeutics Inc subject to activist investor interest2025 Macro Impact & Fast Moving Market Watchlists - khodrobank.com

Sep 19, 2025
pulisher
Sep 19, 2025

Signal strength of Fate Therapeutics Inc. stock in tech scannersStop Loss & Accurate Entry/Exit Alerts - newser.com

Sep 19, 2025
pulisher
Sep 19, 2025

Breakout Zone: Is Fate Therapeutics Incs ROIC above industry averageGlobal Markets & Real-Time Market Trend Scan - khodrobank.com

Sep 19, 2025
pulisher
Sep 19, 2025

Short Covering: Is Fate Therapeutics Inc subject to activist investor interestJuly 2025 Breakouts & Growth Focused Stock Reports - خودرو بانک

Sep 19, 2025
pulisher
Sep 19, 2025

Should you wait for a breakout in Fate Therapeutics Inc.2025 Top Decliners & Safe Capital Growth Tips - newser.com

Sep 19, 2025
pulisher
Sep 19, 2025

Fed Meeting: Is Fate Therapeutics Inc stock risky to hold nowWeekly Investment Recap & Risk Managed Investment Strategies - خودرو بانک

Sep 19, 2025
pulisher
Sep 16, 2025

Portfolio Shifts: Is Fate Therapeutics Inc showing insider buyingMarket Movers & Weekly Stock Performance Updates - خودرو بانک

Sep 16, 2025
pulisher
Sep 16, 2025

Analyst Upgrade: Is Fate Therapeutics Inc showing insider buyingWeekly Investment Summary & AI Driven Stock Price Forecasts - khodrobank.com

Sep 16, 2025
pulisher
Sep 16, 2025

Trading Recap: Is Fate Therapeutics Inc in a bullish channelJuly 2025 Setups & Free AI Powered Buy and Sell Recommendations - خودرو بانک

Sep 16, 2025
pulisher
Sep 16, 2025

Risk Report: Will Fate Therapeutics Inc outperform the market in YEARMarket Movers & Verified Chart Pattern Signals - خودرو بانک

Sep 16, 2025
pulisher
Sep 16, 2025

Jacobs Levy Equity Management Inc. Acquires 616,336 Shares of Fate Therapeutics, Inc. $FATE - MarketBeat

Sep 16, 2025
pulisher
Sep 16, 2025

What analysts say about Fate Therapeutics Inc stockJuly 2025 Recap & High Yield Stock Recommendations - خودرو بانک

Sep 16, 2025
pulisher
Sep 16, 2025

Hedge Fund Bets: Can Fate Therapeutics Inc lead its sector in growth2025 Technical Patterns & Smart Swing Trading Techniques - خودرو بانک

Sep 16, 2025
pulisher
Sep 15, 2025

Momentum Shift: Is Fate Therapeutics Inc stock risky to hold now2025 Fundamental Recap & Reliable Breakout Forecasts - خودرو بانک

Sep 15, 2025
pulisher
Sep 15, 2025

Activity Recap: What is the dividend yield of Fate Therapeutics Inc2025 Major Catalysts & Safe Capital Allocation Plans - خودرو بانک

Sep 15, 2025
pulisher
Sep 15, 2025

Stock Report: Will Fate Therapeutics Inc outperform the market in YEAR2025 Institutional Moves & Technical Buy Zone Confirmation - خودرو بانک

Sep 15, 2025
pulisher
Sep 15, 2025

How to read the order book for Fate Therapeutics Inc.Global Markets & Community Shared Stock Ideas - newser.com

Sep 15, 2025
pulisher
Sep 14, 2025

Should you hold or exit Fate Therapeutics Inc. nowJuly 2025 EndofMonth & Weekly Top Gainers Alerts - newser.com

Sep 14, 2025
pulisher
Sep 13, 2025

Walleye Capital LLC Sells 1,010,806 Shares of Fate Therapeutics, Inc. $FATE - MarketBeat

Sep 13, 2025
pulisher
Sep 12, 2025

Nuveen LLC Purchases Shares of 379,088 Fate Therapeutics, Inc. $FATE - MarketBeat

Sep 12, 2025
pulisher
Sep 10, 2025

Leerink Partnrs Analysts Raise Earnings Estimates for FATE - MarketBeat

Sep 10, 2025
pulisher
Sep 09, 2025

Will Fate Therapeutics Inc. outperform small cap indexesJuly 2025 Chart Watch & Comprehensive Market Scan Reports - Lancaster City Council

Sep 09, 2025
pulisher
Sep 08, 2025

RSI + MACD Show Convergence for Fate Therapeutics Inc.2025 Dividend Review & Weekly Stock Breakout Alerts - beatles.ru

Sep 08, 2025
pulisher
Sep 08, 2025

Analysts Set Fate Therapeutics, Inc. (NASDAQ:FATE) Price Target at $3.30 - MarketBeat

Sep 08, 2025
pulisher
Sep 06, 2025

Price Floor Holding on Fate Therapeutics Inc. — Rebound PossibleJuly 2025 Summary & Verified Short-Term Trading Plans - beatles.ru

Sep 06, 2025
pulisher
Sep 06, 2025

Using data models to predict Fate Therapeutics Inc. stock movementEarnings Recap Summary & Consistent Return Investment Signals - Newser

Sep 06, 2025
pulisher
Sep 05, 2025

Volume spikes in Fate Therapeutics Inc. stock – what they meanGlobal Markets & Risk Adjusted Swing Trade Ideas - Newser

Sep 05, 2025
pulisher
Sep 05, 2025

Heatmap analysis for Fate Therapeutics Inc. and competitorsJuly 2025 Gainers & Free Safe Entry Trade Signal Reports - Newser

Sep 05, 2025
pulisher
Sep 05, 2025

Visual trend scoring systems applied to Fate Therapeutics Inc.Market Trend Report & AI Optimized Trading Strategy Guides - Newser

Sep 05, 2025
pulisher
Sep 05, 2025

What MACD and RSI say about Fate Therapeutics Inc.July 2025 Macro Moves & Reliable Volume Spike Trade Alerts - Newser

Sep 05, 2025
pulisher
Sep 05, 2025

Leerink Partners Sticks to Its Buy Rating for Fate Therapeutics (FATE) - The Globe and Mail

Sep 05, 2025
pulisher
Sep 05, 2025

Layoff Tracker: AC Immune To Cut 30% of Workforce - BioSpace

Sep 05, 2025
pulisher
Sep 05, 2025

Can technical indicators confirm Fate Therapeutics Inc.’s reversalSwing Trade & Stock Market Timing Techniques - Newser

Sep 05, 2025
pulisher
Sep 05, 2025

What are analysts’ price targets for Fate Therapeutics Inc.2025 Market Overview & Smart Swing Trading Alerts - خودرو بانک

Sep 05, 2025
pulisher
Sep 04, 2025

Key metrics from Fate Therapeutics Inc.’s quarterly dataEarnings Recap Summary & Safe Investment Capital Preservation Plans - Newser

Sep 04, 2025
pulisher
Sep 04, 2025

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛

Sep 04, 2025

Fate Therapeutics Inc Stock (FATE) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$34.90
price down icon 2.43%
$81.66
price down icon 2.97%
$28.84
price down icon 2.07%
$98.08
price down icon 1.67%
$135.59
price down icon 3.84%
biotechnology ONC
$328.71
price down icon 0.34%
Cap:     |  Volume (24h):